ScreenerHero

JAZZ Jazz Pharmaceuticals plc

NAS · US · Healthcare · Biotechnology · jazzpharma.com
222.45USD-3.78%Mkt Cap: 14.44B $P/E: 15.25

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (ED…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.70BUSD
CORT
Corcept Therapeutics Incorporated
$12.81BUSDP/E 263.4

Key Statistics

Company
Market Cap14.44B USD
Enterprise Value17.23B USD
Revenue (TTM)4.60B USD
Gross Profit3.76B USD
Net Income (TTM)-356.15M USD
Revenue/Share74.60 USD
Last Price222.45 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.9K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)15.25
P/E (Forward)8.93
PEG0.96
EV/EBITDA8.94
EV/Revenue3.74
P/S3.26
P/B3.12
EPS (TTM)14.30
EPS (Forward)25.92
52W Range
128.8069% of range265.05
52W High265.05 USD
52W Low128.80 USD
Profitability
Gross Margin88.21%
Oper. Margin26.91%
EBITDA Margin41.88%
Profit Margin-8.35%
ROE-8.25%
ROA-3.05%
Growth
Revenue Growth15.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.36B USD
CapEx (TTM)209.75M USD
FCF Margin31.07%
FCF Yield9.90%
Net Debt2.21B USD
Net Debt/EBITDA1.15
Balance Sheet
Debt/Equity1.26
Current Ratio1.78
Quick Ratio1.38
Book Value/Sh74.10 USD
Cash/Share33.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)294.27 USD
Upside (mean)+32.3%
Target Range225.00 USD – 337.00 USD
225.00+32.3% to mean337.00
# Analysts22
Ownership
Shares Out.64.91M
Float62.98M
Insiders2.92%
Institutions102.38%
Short Interest
Short Ratio4.8d
Short % Float7.42%
Short % Out.7.20%
Shares Short4.68M
Short (prev mo.)3.61M
Technical
SMA 50246.38 (-9.7%)
SMA 200212.58 (+4.6%)
Beta0.37
S&P 52W Chg16.45%
Avg Vol (30d)815.08K
Avg Vol (10d)812.45K
Technical Indicators
RSI (14)28.4
MACD-4.4935
MACD Signal-3.5899
MACD Hist.-0.9036
BB Upper248.57 USD
BB Middle237.04 USD
BB Lower225.51 USD
BB Width9.73%
ATR (14)6.956 USD
Vol Ratio (20d)1.58x